Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 3/20 | 0.53 |
| ▸ | RXRA | P19793 | 2/20 | 0.53 |
| ▸ | RXRG | P48443 | 2/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035750 | 0.93 | MAPT (0.61) | FFAR4SLC22A12POLBMAPTTHRB | |
| SCHEMBL9077917 | 0.91 | SLC2A1 (0.52) | FFAR4SLC22A12FFAR1SLC2A1MTNR1A | |
| SCHEMBL9076148 | 0.91 | SLC2A1 (0.52) | FFAR4SLC22A12FFAR1SLC2A1MTNR1A | |
| SCHEMBL1114985 | 0.91 | NPC1 (0.63) | RXRAPTGER4PTGER2MTNR1AMTNR1B | |
| SCHEMBL31011346 | 0.91 | NPC1 (0.63) | RXRAPTGER4PTGER2MTNR1AMTNR1B | |
| SCHEMBL2391945 | 0.91 | SMPD1 (0.61) | FFAR4FFAR1RXRAMTNR1AMTNR1B | |
| SCHEMBL6214774 | 0.87 | FOLH1 (0.51) | FFAR4FFAR1FOLH1RXRASLC2A1 | |
| SCHEMBL8072945 | 0.87 | PTGER1 (0.52) | FFAR4FFAR1FOLH1RXRBRXRA | |
| SCHEMBL8975189 | 0.87 | MTNR1A (0.54) | FFAR4FOLH1RXRASLC2A1POLB | |
| SCHEMBL10477771 | 0.87 | FOLH1 (0.55) | FFAR4FFAR1FOLH1RXRASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115212314-A | Albumin-bound antitumor drug and nano-composite thereof, and preparation method and application thereof | 沈阳药科大学 | 2022-10-21 | — | — | CN | claimed |
| US-20240217945-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | ARCADIA MEDICINE, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-115212314-B | Albumin combined anti-tumor medicine and nano-composite thereof, preparation method and application | 沈阳药科大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-114195640-B | Synthesis process of hydroxytyrosol and intermediate thereof | 攀枝花学院 | 2024-03-12 | — | — | CN | disclosed |
| US-20230382885-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | ARCADIA MEDICINE, INC. | 2023-11-30 | — | — | US | disclosed |
| CN-116444569-A | Triphenylhydroxytyrosol and synthesis method thereof and application of triphenylhydroxytyrosol in preparation of medicines for improving aortic endothelial cell functions | 西安交通大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-115850334-A | Triphenylphosphonium-hydroxytyrosol, synthesis method thereof and application thereof in preparing drugs for inhibiting cancer cell proliferation | 西安交通大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-115212314-A | Albumin-bound antitumor drug and nano-composite thereof, and preparation method and application thereof | 沈阳药科大学 | 2022-10-21 | — | — | CN | disclosed |
| CN-114195640-A | Synthetic process of hydroxytyrosol and intermediate thereof | 攀枝花学院 | 2022-03-18 | — | — | CN | disclosed |
| CN-108276367-B | Bromo-furanone ester compound and preparation method and application thereof | 暨南大学 | 2020-05-08 | — | — | CN | disclosed |
| EP-2086922-A2 | ISOLATED HYDROXY AND N-OXIDE METABOLITES AND DERIVATIVES OF O-DESMETHYLVENLAFAXINE AND METHODS OF TREATMENT | Wyeth (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080261895-A1 | Isolated hydroxy and n-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment | WYETH | 2008-10-23 | — | — | US | disclosed |
| WO-2008051558-A2 | ISOLATED HYDROXY AND N-OXIDE METABOLITES AND DERIVATIVES OF O-DESMETHYLVENLAFAXINE AND METHODS OF TREATMENT | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008047382-A2 | A PROCESS FOR THE PREPARATION OF 4-[2-[[3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]AMINO]ETHYL]-1,2-BENZENEDIOL | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-04-24 | — | — | WO | disclosed |
| US-5665765-A | TREATMENT OF PARKINSON'S DISEASE, MEMORY DISORDERS, DISORDERS ASSOCIATED WITH DRUG ABUSE, DEPRESSION, AND PSYCHOTIC STATES | ADIR ET COMPAGNIE (FR) | 1997-09-09 | — | — | US | disclosed |
| US-5047430-A | Glutamate Receptor Inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| US-4990511-A | Amide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
| EP-0353753-A1 | Amide compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| EP-0339927-A2 | Amide compounds their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-11-02 | — | — | EP | disclosed |
| EP-0215736-A1 | Xanthine derivatives, processes for their production and their use as pharmaceuticals | SANDOZ AG (CH) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217945-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | HTR1A, PNMT, HTR2C | FFAR4 2397/4885SLC22A12 948/4885FFAR1 2787/4885 |
| US-20080261895-A1 | Isolated hydroxy and n-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment | UGT1A4, SLC6A4, UGT1A3 | FFAR4 181/4885SLC22A12 652/4885FFAR1 514/4885 |
| US-20230382885-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | HTR1A, PNMT, HTR2C | FFAR4 2397/4885SLC22A12 948/4885FFAR1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.